Real-World Outcomes

Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
A commonly used gene expression profile test for predicting breast cancer recurrence proves to be less cost-effective in a real-world setting, according to research published in the Journal of Clinical Oncology.
Receiving care in a community setting is associated with a prolonged maintenance treatment in patients with non-Hodgkin lymphoma.
A recently approved second-line therapy is reasonably effective in the treatment of advanced non-small cell lung cancer, according to a recent real-world study.
Differences in health insurance coverage account for about half of the substantial disparity in survival between black and white patients with colorectal cancer.
Student pharmacists can accurately and efficiently acquire medication histories for patients admitted to a large academic hospital, reducing the workload of the clinical staff.
More than 60% of patients prescribed antiretroviral therapy at a large community teaching hospital experienced at least one prescription error.
A recent study found that while treatment outcomes for a CLL therapy are comparable in clinical trials and the real-world setting, adverse events are increased in the latter.
Laws designed to equalize out-of-pocket costs faced by cancer patients undergoing chemotherapy — whether treated intravenously, with pills or liquid doses — are having mixed results.
Duke Cancer Institute has developed a community health program focused on minimizing cancer disparities and improving overall health.